153 related articles for article (PubMed ID: 33545641)
1. Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation.
Cui S; Shin YJ; Ko EJ; Lim SW; Ju JH; Lee KI; Lee JY; Yang CW; Chung BH
Stem Cell Res; 2021 Mar; 51():102214. PubMed ID: 33545641
[TBL] [Abstract][Full Text] [Related]
2. Generation of the human induced pluripotent stem cell lines (CMCi009-A) from a patient with Birt-Hogg-Dubé syndrome (BHD) with heterozygous frameshift deletion mutation c.1285delC of the FLCN gene.
Ko EJ; Cui S; Shin YJ; Lim SW; Lee KI; Lee JY; Yang CW; Kim M; Chung BH
Stem Cell Res; 2021 Mar; 51():102215. PubMed ID: 33540282
[TBL] [Abstract][Full Text] [Related]
3. Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system.
Cui S; Fang X; Lee H; Shin YJ; Koh ES; Chung S; Park HS; Lim SW; Lee KI; Lee JY; Yang CW; Chung BH
J Transl Med; 2023 Feb; 21(1):138. PubMed ID: 36814269
[TBL] [Abstract][Full Text] [Related]
4. Generation of a human induced pluripotent stem cell line (CMCi001-A) from a patient with karyomegalic interstitial nephritis with homozygous frameshift deletion mutation c.1985_1994del10 of the FANCD2/FANCI-Associated Nuclease 1 gene.
Na DH; Lim SW; Kim BM; Kim KW; Shin YJ; Chae H; Ko EJ; Yang CW; Kim M; Chung BH
Stem Cell Res; 2020 Jul; 46():101876. PubMed ID: 32563974
[TBL] [Abstract][Full Text] [Related]
5. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
6. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
7. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
8. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
9. Generation of the induced pluripotent stem cell line UKWNLi005-A derived from a patient with the GLA mutation c.376A > G of unknown pathogenicity in Fabry disease.
Breyer M; Klein T; Klug K; Klopocki E; Üçeyler N
Stem Cell Res; 2022 May; 61():102747. PubMed ID: 35325818
[TBL] [Abstract][Full Text] [Related]
10. Generation of the human induced pluripotent stem cell line (UKWNLi001-A) from skin fibroblasts of a woman with Fabry disease carrying the X-chromosomal heterozygous c.708 G > C (W236C) missense mutation in exon 5 of the alpha-galactosidase-A gene.
Klein T; Günther K; Kwok CK; Edenhofer F; Üçeyler N
Stem Cell Res; 2018 Aug; 31():222-226. PubMed ID: 30130681
[TBL] [Abstract][Full Text] [Related]
11. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease.
Colomba P; Nucera A; Zizzo C; Albeggiani G; Francofonte D; Iemolo F; Tuttolomondo A; Pinto A; Duro G
Clin Biochem; 2012 Jul; 45(10-11):839-41. PubMed ID: 22465271
[TBL] [Abstract][Full Text] [Related]
13. Maternal germline mosaicism in Fabry disease.
Pianese L; Fortunato A; Silvestri S; Solano FG; Burlina A; Burlina AP; Ragno M
Neurol Sci; 2019 Jun; 40(6):1279-1281. PubMed ID: 30762167
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.
Cui S; Shin YJ; Fang X; Lee H; Eum SH; Ko EJ; Lim SW; Shin E; Lee KI; Lee JY; Lee CB; Bae SK; Yang CW; Chung BH
Transl Res; 2023 Aug; 258():35-46. PubMed ID: 36805562
[TBL] [Abstract][Full Text] [Related]
16. Generation of an induced pluripotent stem cell line (ZJUi007-A) from a 11-year-old patient of Fabry disease.
Zhu Y; Zhang L; Wang G; Zhao J; Hou X; Wu H; Xu Y; Mao J; Liu Z; Zhang J
Stem Cell Res; 2021 Aug; 55():102475. PubMed ID: 34365103
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of iPS cell line (CTGUi001-A) from skin fibroblasts of a patient with Fabry disease.
Qin Y; Zhan JQ; Ma CJ; Cao CY; Zhang Y; Min YT; Lv YF
Stem Cell Res; 2023 Jun; 69():103063. PubMed ID: 36917862
[TBL] [Abstract][Full Text] [Related]
18. Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.
Kobayashi M; Ohashi T; Kaneshiro E; Higuchi T; Ida H
J Hum Genet; 2019 Jul; 64(7):695-699. PubMed ID: 30988410
[TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cell line (INSAi002-A) from a Fabry Disease patient hemizygote for the rare p.W287X mutation.
Duarte AJ; Ribeiro D; Santos R; Moreira L; Bragança J; Amaral O
Stem Cell Res; 2020 May; 45():101794. PubMed ID: 32388441
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.
Chien Y; Chien CS; Chiang HC; Huang WL; Chou SJ; Chang WC; Chang YL; Leu HB; Chen KH; Wang KL; Lai YH; Liu YY; Lu KH; Li HY; Sung YJ; Jong YJ; Chen YJ; Chen CH; Yu WC
Oncotarget; 2016 Dec; 7(52):87161-87179. PubMed ID: 27888626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
